Harper Ellsworth Advertising, alongside its client Texas Radiotherapy, has been named a finalist for the 2024 MM+M Awards in the 'Use of Hospital or Healthcare Services Marketing' category. The MM+M Awards are known for recognizing creativity and effectiveness in healthcare marketing, with the winners being chosen through a rigorous judging process by over 90 industry experts.
The finalists, including Harper Ellsworth, are set to attend the awards gala in New York City on October 10, 2024. This event is highly regarded in the industry, making the nomination a significant accolade. According to MM+M's Larry Dobrow, the awards celebrate marketing efforts that contribute to better health outcomes, underscoring the impact of the work done by agencies like Harper Ellsworth.
Kathlene Simmons, CEO of Harper Ellsworth, expressed her excitement about the nomination, emphasizing that it reflects the collaborative efforts of her team to raise awareness about prostate cancer through their campaign for Texas Radiotherapy. Melvin Strobbe, Project Creative Director, credited the success to the strong partnership with Texas Radiotherapy and the authentic patient stories that formed the core of their strategy.
For more information about the 2024 MM+M Awards, visit https://www.mmm-awards.com.
Harper Ellsworth's recognition in the MM+M Awards not only highlights the agency's creative prowess but also its commitment to impactful healthcare marketing. This acknowledgment could potentially enhance the agency's reputation within the industry and attract new client opportunities, further driving innovation in healthcare communications.
